BR112020017541A2 - Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt - Google Patents

Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt Download PDF

Info

Publication number
BR112020017541A2
BR112020017541A2 BR112020017541-2A BR112020017541A BR112020017541A2 BR 112020017541 A2 BR112020017541 A2 BR 112020017541A2 BR 112020017541 A BR112020017541 A BR 112020017541A BR 112020017541 A2 BR112020017541 A2 BR 112020017541A2
Authority
BR
Brazil
Prior art keywords
6alkyl
6alkoxy
chosen
compound
haloc1
Prior art date
Application number
BR112020017541-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Emilia Di Francesco
Philip Jones
Timothy McAfoos
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of BR112020017541A2 publication Critical patent/BR112020017541A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020017541-2A 2018-03-01 2019-03-01 Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt BR112020017541A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637147P 2018-03-01 2018-03-01
US62/637,147 2018-03-01
PCT/US2019/020395 WO2019169326A1 (en) 2018-03-01 2019-03-01 Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

Publications (1)

Publication Number Publication Date
BR112020017541A2 true BR112020017541A2 (pt) 2020-12-22

Family

ID=67767960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020017541-2A BR112020017541A2 (pt) 2018-03-01 2019-03-01 Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt

Country Status (8)

Country Link
US (2) US11028083B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758698A4 (cg-RX-API-DMAC7.html)
JP (1) JP7305664B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867584A (cg-RX-API-DMAC7.html)
AU (1) AU2019226585A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017541A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092579A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019169326A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt
WO2022192527A1 (en) * 2021-03-12 2022-09-15 Board Of Regents, The University Of Texas System Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
JP2004149429A (ja) * 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
EP2221053A1 (de) * 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
US9593109B2 (en) * 2011-08-26 2017-03-14 Cymabay Therapeutics, Inc. Bicyclic agonists of GPR131 and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) * 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903394C (en) * 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム,インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
EP3363434A1 (en) * 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) * 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) * 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) * 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9394258B2 (en) * 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
US20170280720A1 (en) * 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044626A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
KR102148587B1 (ko) 2016-02-23 2020-08-26 화이자 인코포레이티드 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt

Also Published As

Publication number Publication date
EP3758698A1 (en) 2021-01-06
WO2019169326A1 (en) 2019-09-06
CN111867584A (zh) 2020-10-30
US11028083B2 (en) 2021-06-08
JP7305664B2 (ja) 2023-07-10
US20190270739A1 (en) 2019-09-05
CA3092579A1 (en) 2019-09-06
AU2019226585A1 (en) 2020-10-08
US20230027126A1 (en) 2023-01-26
EP3758698A4 (en) 2021-10-20
US11725008B2 (en) 2023-08-15
JP2021514999A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2019263294B2 (en) Substituted heterocyclic inhibitors of PTPN11
JP7290627B2 (ja) Atrキナーゼの複素環式阻害剤
AU2017274199B2 (en) Heterocyclic inhibitors of PTPN11
AU2023248127A1 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
BR112019026678A2 (pt) indolinas espirocíclicas como moduladores de il-17
US10745420B2 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
KR102664604B1 (ko) 이환형 케톤 화합물 및 이의 사용 방법
BR112020019824A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente
CN101903384A (zh) 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物
AU2016258188B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
WO2009032754A2 (en) Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2021108198A1 (en) Inhibitors of receptor interacting protein kinase i for the treatment of disease
US11725008B2 (en) Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
CN116261557B (zh) 作为keap1调节剂的环状氰基烯酮衍生物
WO2022192527A1 (en) Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
AU2024287908A1 (en) Tetrahydroquinazoline derivatives as selective cytotoxic agents

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements